I hold a little of this one and think it is a good business, as they accelerate revenues out of amalgam and into aesthetics which is now 45% of revenue.
However, they have just announced their business has been impacted with closure of many dental studios. This means NPAT likely $3.5-4.5m vs $7.3m last year. But at $83m market cap and little debt, I think its likely to weather the crisis ok.
In the short-term, may well retest 50c lows though, which would make it very compelling buy because likely a snap back in dental restocking once studios do reopen.
Also, the low AUD is now a strong tailwind for the Aussie-based manufacturer.
However, they have just announced their business has been impacted with closure of many dental studios. This means NPAT likely $3.5-4.5m vs $7.3m last year. But at $83m market cap and little debt, I think its likely to weather the crisis ok.
In the short-term, may well retest 50c lows though, which would make it very compelling buy because likely a snap back in dental restocking once studios do reopen.
Also, the low AUD is now a strong tailwind for the Aussie-based manufacturer.